SLC5A2 and coronary artery disorder: In another retrospective observational study, including 420 patients with a recent diagnosis of CAD and concomitant type 2 DM, it was assessed whether initiation of an SGLT-2 inhibitor at discharge had a more favorable impact on surrogate cardiovascular outcomes [44].